Metabolism and Metabolite Markers in Type 2 Diabetes

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (15 November 2021) | Viewed by 24883

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, 751 85 Uppsala, Sweden
Interests: diabetology; metabolism; insulin resistance; adipose tissue in diabetes; diabetic complications
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear colleagues,

Type 2 diabetes currently causes a major global disease burden, both to the approximately 500 million affected patients and to healthcare systems and society. Treatment options have improved lately and can reduce the risk of devastating organ complications and premature death. They include modern medications to control hyperglycemia and also other risk factors such as hypertension, dyslipidemia, and obesity. To enable optimal disease management in the future, there is nontheless  a need for better disease understanding and characterization of important metabolic pathways and biomolecules. This will support advancement of precision medicine in type 2 diabetes, which may provide innovative and individualized tools for prevention, diagnosis, prognosis, and therepy.

This Special Issue of Metabolites will focus on advances in the field of metabolic regulation and dysregulation relevant to the development, progression, and reversal of type 2 diabetes. Its scope includes, but is not limited to, the pathobiology of cellular signaling, metabolism, and hormone secretion and action. Original research and review papers are welcome and may focus on specific molecular mechanisms and drug targets, metabolic networks, as well as cell and tissue crosstalk. Studies may, for example, utilize metabolomics, but also proteomics, transcriptomics, and microbiomics. We very much look forward to your important contributions to this exciting Special Issue.

Prof. Dr. Jan W. Eriksson
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glucose metabolism
  • energy metabolism
  • lipids
  • hormone secretion
  • insulin resistance
  • signaling
  • tissue crosstalk

Published Papers (8 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

2 pages, 174 KiB  
Editorial
Special Issue on Metabolism and Metabolite Markers in Type 2 Diabetes
by Jan W. Eriksson
Metabolites 2022, 12(7), 642; https://doi.org/10.3390/metabo12070642 - 13 Jul 2022
Viewed by 829
Abstract
It is well recognized that type 2 diabetes poses a major and increasing public health challenge, and presently, almost 500 million individuals around the globe are diagnosed with this condition [...] Full article
(This article belongs to the Special Issue Metabolism and Metabolite Markers in Type 2 Diabetes)

Research

Jump to: Editorial, Review

14 pages, 2429 KiB  
Article
Attenuation of Olanzapine-Induced Endoplasmic Reticulum Stress Improves Insulin Secretion in Pancreatic Beta Cells
by Diana Grajales, Patricia Vázquez, Rosa Alén, Ana B. Hitos and Ángela M. Valverde
Metabolites 2022, 12(5), 443; https://doi.org/10.3390/metabo12050443 - 16 May 2022
Cited by 5 | Viewed by 2329
Abstract
Second-generation antipsychotics (SGAs), in particular, olanzapine and clozapine, have been associated with the development of type 2 diabetes mellitus (T2D) and metabolic syndrome in individuals with schizophrenia. In this context, beta cell dysfunction is a plausible mechanism by which SGAs cause T2D. Herein, [...] Read more.
Second-generation antipsychotics (SGAs), in particular, olanzapine and clozapine, have been associated with the development of type 2 diabetes mellitus (T2D) and metabolic syndrome in individuals with schizophrenia. In this context, beta cell dysfunction is a plausible mechanism by which SGAs cause T2D. Herein, we analyzed the direct effects of olanzapine, a commonly prescribed SGA with diabetogenic properties, on the INS-1 (821/13) beta cell line and isolated pancreatic islets. Treatment of INS-1 beta cells with non-toxic concentrations of olanzapine (3–6 μM) during 4 h activated endoplasmic reticulum (ER) stress-mediated signaling by increasing PERK/eIF2α phosphorylation, IRE-1 phosphorylation and XBP-1 splicing. Moreover, glucose-stimulated insulin secretion (GSIS) was inhibited when olanzapine was present for 16 h. The insulin secretory function of INS-1 cells was restored by inhibiting olanzapine-induced ER stress with tauroursodeoxycholic acid (TUDCA). Similar effects of olanzapine with or without TUDCA on ER-stress-mediated signaling and GSIS were found in pancreatic islets from female mice. Our results indicate that early activation of ER stress in pancreatic beta cells is a potential mechanism behind the alterations in glucose homeostasis induced by olanzapine. Full article
(This article belongs to the Special Issue Metabolism and Metabolite Markers in Type 2 Diabetes)
Show Figures

Graphical abstract

14 pages, 1898 KiB  
Article
Microbiome, Mycobiome and Related Metabolites Alterations in Patients with Metabolic Syndrome—A Pilot Study
by Gratiela Gradisteanu Pircalabioru, Iuliana Ilie, Luciana Oprea, Ariana Picu, Laura Madalina Petcu, Liliana Burlibasa, Mariana-Carmen Chifiriuc and Madalina Musat
Metabolites 2022, 12(3), 218; https://doi.org/10.3390/metabo12030218 - 28 Feb 2022
Cited by 12 | Viewed by 2643
Abstract
Metabolic syndrome (MetSyn) has a rapidly growing worldwide prevalence, affecting over 1 billion people. MetSyn is clustering many pathological conditions, which, untreated, could increase the risk and often lead to more severe metabolic defects such as type 2 diabetes and non-alcoholic fatty liver [...] Read more.
Metabolic syndrome (MetSyn) has a rapidly growing worldwide prevalence, affecting over 1 billion people. MetSyn is clustering many pathological conditions, which, untreated, could increase the risk and often lead to more severe metabolic defects such as type 2 diabetes and non-alcoholic fatty liver disease. Many data demonstrate the complex role of gut microbiota in the host metabolism, and hence, deciphering the microbiome patterns linked to MetSyn could enable us for novel diagnosis and monitoring markers and for better disease management. Moreover, interventions designed to alter patient microbiome composition may help prevent or decrease morbidity linked with MetSyn. However, the microbiome composition is largely different across geographically distinct populations. Our study investigated the microbiota and mycobiome patterns in Romanian metabolic syndrome patients. We also correlated the identified microbiome–mycobiome patterns with levels of metabolites important for host health such as short chain fatty acids, organic acids, and taurine. We found that MetSyn patients are harboring a microbiome enriched in Enterobacteriaceae, Turicibacter sp., Clostridium coccoides, and Clostridium leptum, while beneficial taxa such as Butyricicoccus sp., Akkermansia muciniphila, and Faecalibacterium prausnitzii were decreased. These microbiome changes were correlated with lower butyrate levels and increased succinate. In terms of mycobiome signatures, MetSyn was associated with a high abundance of Saccharomyces and Aspergillus species. Our data are the first reported on a Romanian population and confirming that the pathogenesis of MetSyn is closely related to gut microbiome and homeostasis. Full article
(This article belongs to the Special Issue Metabolism and Metabolite Markers in Type 2 Diabetes)
Show Figures

Graphical abstract

22 pages, 3446 KiB  
Article
Effect of n-3 (Omega-3) Polyunsaturated Fatty Acid Supplementation on Metabolic and Inflammatory Biomarkers and Body Weight in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of RCTs
by Leila Khalili, Roxana Valdes-Ramos and Laurence S. Harbige
Metabolites 2021, 11(11), 742; https://doi.org/10.3390/metabo11110742 - 28 Oct 2021
Cited by 24 | Viewed by 3614
Abstract
Beneficial effects of n-3 fatty acids on metabolic biomarkers in patients with type 2 diabetes (T2DM) has been reported. The objectives of this current research were to investigate the effects of n-3 supplementation on metabolic factors, weight, and body mass index [...] Read more.
Beneficial effects of n-3 fatty acids on metabolic biomarkers in patients with type 2 diabetes (T2DM) has been reported. The objectives of this current research were to investigate the effects of n-3 supplementation on metabolic factors, weight, and body mass index (BMI) in patients with type 2 diabetes mellitus (T2DM), using a meta-analysis of randomized, controlled trials (RCTs). Online databases PubMed, Embase, Web of Science, and Science Direct were searched until 2021 to identify eligible articles. Thirty trials were included. The results showed that n-3 consumption can significantly reduce glycemic factors including fasting blood sugar (FBS) (−0.36 (−0.71 to −0.01)), glycated hemoglobulin (HbA1c) (−0.74 (−1.13 to −0.35)), and homeostatic model assessment of insulin resistance (HOMA.IR) (−0.58 (−1.13 to −0.03)). Furthermore, significant improvement in lipid profile including triglycerides (TG) (−0.27 (−0.37 to −0.18)), total cholesterol (−0.60 (−0.88 to −0.32)), low density lipoprotein (LDL) (−0.54 (−0.85 to −0.23)), and high-density lipoprotein (HDL) (0.60 (0.23 to 0.96)) levels were found in the present meta-analysis. The reduction in the inflammatory marker’s tumor necrosis factor-alpha (TNF-α) (−0.13 (−0.75 to 0.48)) and c-reactive protein (CRP) (−0.72 (−1.70 to 0.27)), as well as weight (−0.09 (−0.24 to 0.07)) and BMI (−0.13 (−0.29 to 0.02)) were not statistically significant. Furthermore, the findings revealed that the optimal dose and duration of n-3 consumption for patients with T2DM is 1000–2000 mg/d for more than 8 weeks. The present meta-analysis and review reveals that n-3 supplementation can improve glycemic factors and lipid profile in patients with T2DM. Furthermore, n-3 supplementation may provide beneficial effects on inflammatory markers and body weight if used at the appropriate dose and duration. Full article
(This article belongs to the Special Issue Metabolism and Metabolite Markers in Type 2 Diabetes)
Show Figures

Figure 1

22 pages, 1957 KiB  
Article
Impaired HMG-CoA Reductase Activity Caused by Genetic Variants or Statin Exposure: Impact on Human Adipose Tissue, β-Cells and Metabolome
by Assel Sarsenbayeva, Bipasha Nandi Jui, Giovanni Fanni, Pedro Barbosa, Fozia Ahmed, Robin Kristófi, Jing Cen, Azazul Chowdhury, Stanko Skrtic, Peter Bergsten, Tove Fall, Jan W. Eriksson and Maria J. Pereira
Metabolites 2021, 11(9), 574; https://doi.org/10.3390/metabo11090574 - 25 Aug 2021
Cited by 6 | Viewed by 5523
Abstract
Inhibition of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase is associated with an increased risk of new-onset type 2 diabetes. We studied the association of genetic or pharmacological HMG-CoA reductase inhibition with plasma and adipose tissue (AT) metabolome and AT metabolic pathways. We also investigated the effects [...] Read more.
Inhibition of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase is associated with an increased risk of new-onset type 2 diabetes. We studied the association of genetic or pharmacological HMG-CoA reductase inhibition with plasma and adipose tissue (AT) metabolome and AT metabolic pathways. We also investigated the effects of statin-mediated pharmacological inhibition of HMG-CoA reductase on systemic insulin sensitivity by measuring the HOMA-IR index in subjects with or without statin therapy. The direct effects of simvastatin (20–250 nM) or its active metabolite simvastatin hydroxy acid (SA) (8–30 nM) were investigated on human adipocyte glucose uptake, lipolysis, and differentiation and pancreatic insulin secretion. We observed that the LDL-lowering HMGCR rs12916-T allele was negatively associated with plasma phosphatidylcholines and sphingomyelins, and HMGCR expression in AT was correlated with various metabolic and mitochondrial pathways. Clinical data showed that statin treatment was associated with HOMA-IR index after adjustment for age, sex, BMI, HbA1c, LDL-c levels, and diabetes status in the subjects. Supra-therapeutic concentrations of simvastatin reduced glucose uptake in adipocytes and normalized fatty acid-induced insulin hypersecretion from β-cells. Our data suggest that inhibition of HMG-CoA reductase is associated with insulin resistance. However, statins have a very mild direct effect on AT and pancreas, hence, other tissues as the liver or muscle appear to be of greater importance. Full article
(This article belongs to the Special Issue Metabolism and Metabolite Markers in Type 2 Diabetes)
Show Figures

Graphical abstract

9 pages, 990 KiB  
Article
Patterns and Associations of Essential Trace Elements (Cu, Fe and Zn) in Saudi Adults with Varying Levels of Glycemia
by Sobhy Yakout, Fatimah Faqeeh, Omar Al-Attas, Syed D. Hussain and Nasser M. Al-Daghri
Metabolites 2021, 11(5), 297; https://doi.org/10.3390/metabo11050297 - 06 May 2021
Cited by 1 | Viewed by 2110
Abstract
The homeostasis of trace elements were observed to contribute to certain diabetic outcomes. This cross-sectional study determined the differences and associations between serum levels of copper (Cu), iron (Fe) and zinc (Zn) in Saudi patients with and without type 2 diabetes mellitus (T2DM) [...] Read more.
The homeostasis of trace elements were observed to contribute to certain diabetic outcomes. This cross-sectional study determined the differences and associations between serum levels of copper (Cu), iron (Fe) and zinc (Zn) in Saudi patients with and without type 2 diabetes mellitus (T2DM) as well as those with prediabetes. Anthropometrics were measured, and fasting blood samples were collected from 119 patients with T2DM (aged 41–64 years), 95 non-T2DM (aged 27–55 years) and 80 with prediabetes (aged 35–57 years). Circulating trace minerals were determined using an inductively coupled plasma–mass spectrometer. Serum levels of Cu and Fe were significantly lower in T2DM than non-T2DM (adjusted p-values < 0.001). There was no difference in the Zn levels of the T2DM and non-T2DM groups. The serum Cu levels were significantly lower in the prediabetes group than the non-T2DM group (p < 0.05). The serum levels of Cu, Fe and Zn were inversely associated with circulating glucose in the T2DM and prediabetes subjects (p-values < 0.001). In conclusion, the differences in circulating trace elements were observed in Saudi subjects with varying glycemic statuses, suggesting an inverse association between T2DM progression and the decreasing serum Cu, Fe and Zn levels. Intervention trials are warranted to determine whether early correction of trace mineral deficiencies is beneficial in populations at higher risk for T2DM. Full article
(This article belongs to the Special Issue Metabolism and Metabolite Markers in Type 2 Diabetes)
Show Figures

Figure 1

Review

Jump to: Editorial, Research

19 pages, 400 KiB  
Review
Potential Mechanisms for How Long-Term Physical Activity May Reduce Insulin Resistance
by Sindre Lee-Ødegård, Thomas Olsen, Frode Norheim, Christian Andre Drevon and Kåre Inge Birkeland
Metabolites 2022, 12(3), 208; https://doi.org/10.3390/metabo12030208 - 25 Feb 2022
Cited by 2 | Viewed by 3294
Abstract
Insulin became available for the treatment of patients with diabetes 100 years ago, and soon thereafter it became evident that the biological response to its actions differed markedly between individuals. This prompted extensive research into insulin action and resistance (IR), resulting in the [...] Read more.
Insulin became available for the treatment of patients with diabetes 100 years ago, and soon thereafter it became evident that the biological response to its actions differed markedly between individuals. This prompted extensive research into insulin action and resistance (IR), resulting in the universally agreed fact that IR is a core finding in patients with type 2 diabetes mellitus (T2DM). T2DM is the most prevalent form of diabetes, reaching epidemic proportions worldwide. Physical activity (PA) has the potential of improving IR and is, therefore, a cornerstone in the prevention and treatment of T2DM. Whereas most research has focused on the acute effects of PA, less is known about the effects of long-term PA on IR. Here, we describe a model of potential mechanisms behind reduced IR after long-term PA to guide further mechanistic investigations and to tailor PA interventions in the therapy of T2DM. The development of such interventions requires knowledge of normal glucose metabolism, and we briefly summarize an integrated physiological perspective on IR. We then describe the effects of long-term PA on signaling molecules involved in cellular responses to insulin, tissue-specific functions, and whole-body IR. Full article
(This article belongs to the Special Issue Metabolism and Metabolite Markers in Type 2 Diabetes)
Show Figures

Graphical abstract

28 pages, 2593 KiB  
Review
The Role of Nutraceutical Containing Polyphenols in Diabetes Prevention
by Iva Fernandes, Joana Oliveira, Aryane Pinho and Eugenia Carvalho
Metabolites 2022, 12(2), 184; https://doi.org/10.3390/metabo12020184 - 17 Feb 2022
Cited by 18 | Viewed by 3694
Abstract
Research in pharmacological therapy has led to the availability of many antidiabetic agents. New recommendations for precision medicine and particularly precision nutrition may greatly contribute to the control and especially to the prevention of diabetes. This scenario greatly encourages the search for novel [...] Read more.
Research in pharmacological therapy has led to the availability of many antidiabetic agents. New recommendations for precision medicine and particularly precision nutrition may greatly contribute to the control and especially to the prevention of diabetes. This scenario greatly encourages the search for novel non-pharmaceutical molecules. In line with this, the daily and long-term consumption of diets rich in phenolic compounds, together with a healthy lifestyle, may have a protective role against the development of type 2 diabetes. In the framework of the described studies, there is clear evidence that the bio accessibility, bioavailability, and the gut microbiota are indeed affected by: the way phenolic compounds are consumed (acutely or chronically; as pure compounds, extracts, or in-side a whole meal) and the amount and the type of phenolic compounds (ex-tractable or non-extractable/macromolecular antioxidants, including non-bioavailable polyphenols and plant matrix complexed structures). In this review, we report possible effects of important, commonly consumed, phenolic-based nutraceuticals in pre-clinical and clinical diabetes studies. We highlight their mechanisms of action and their potential effects in health promotion. Translation of this nutraceutical-based approach still requires more and larger clinical trials for better elucidation of the mechanism of action toward clinical applications. Full article
(This article belongs to the Special Issue Metabolism and Metabolite Markers in Type 2 Diabetes)
Show Figures

Figure 1

Back to TopTop